7 completed, 1 active not recruiting, 1 terminated. 9 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 9 | Completed 7, Active not recruiting 1, Terminated 1 |
Follow EIP Pharma Inc: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Clinical Study of Neflamapimod in Patients With Primary Progressive Aphasia Neflamapimod, Placebo - Nonfluent Variant Primary Progressive Aphasia (nfvPPA) | Phase 2 | Active not recruiting | EIP Pharma Inc | 20 | 2025-10-02 | 2026-07-06 |
| A Clinical Study to Investigate the Effect of Oral Neflamapimod on Motor Recovery After Acute Ischaemic Stroke Neflamapimod, Placebo - Moderate to Severe Acute Ischaemic Stroke, Ischaemic Stroke | Phase 2 | Completed | EIP Pharma Inc | 45 | 2025-06-20 | 2026-10-28 |
| A Clinical Study of Neflamapimod in Patients With Dementia With Lewy Bodies neflamapimod - Dementia With Lewy Bodies (DLB) | Phase 2 | Completed | EIP Pharma Inc | 26 | 2024-10-16 | 2026-07-08 |
| RewinD-LB - Clinical Study of Neflamapimod in Patients With Dementia With Lewy Bodies Neflamapimod, Placebo - Dementia With Lewy Bodies | Phase 2 | Completed | EIP Pharma Inc | 159 | 2023-05-01 | 2026-09-03 |
| Cognitive Effects of Oral p38 Alpha Kinase Inhibitor Neflamapimod in Dementia With Lewy Bodies Neflamapimod - Dementia With Lewy Bodies (DLB) | Phase 2 | Completed | EIP Pharma Inc | 91 | 2019-09-30 | 2023-06-29 |
| Within Subject Crossover Study of Cognitive Effects of Neflamapimod in Early-Stage Huntington Disease neflamapimod, Placebo - Huntington Disease | Phase 2 | Terminated | EIP Pharma Inc | 15 | 2019-07-08 | 2022-04-06 |
| Proof-of-Concept Study of a Selective p38 MAPK Alpha Inhibitor, Neflamapimod, in Subjects With Mild Alzheimer's Disease neflamapimod, placebo - Alzheimer Disease | Phase 2 | Completed | EIP Pharma Inc | 161 | 2017-12-29 | 2021-10-27 |
| A PET Study of the Effects of p38 MAP Kinase Inhibitor, VX-745, on Amyloid Plaque Load in Alzheimer's Disease (AD) VX-745 - Alzheimer's Disease, Mild Cognitive Impairment | Phase 2 | Completed | EIP Pharma Inc | 16 | 2015-04-01 | 2019-06-14 |
| Clinical Pharmacology of p38 MAP Kinase Inhibitor, VX-745, in Mild Cognitive Impairment Due to Alzheimer's Disease (AD) or Mild AD VX-745 - Alzheimer's Disease | Phase 2 | Completed | EIP Pharma Inc | 16 | 2015-04-01 | 2018-04-03 |
Alzheimer Disease (3) · Lewy Body Disease (3) · Aphasia (1) · Aphasia, Primary Progressive (1) · Brain Diseases (1) · Central Nervous System Diseases (1) · Cognitive Dysfunction (1) · Dementia (1) · Frontotemporal Dementia (1) · Huntington Disease (1) · Ischemic Stroke (1) · Language Disorders (1) · Mental Disorders (1) · Nervous System Diseases (1) · Neurocognitive Disorders (1)
VX-745 (7)
United States (5) · Netherlands (4) · United Kingdom (4) · Australia (1) · Czechia (1) · Denmark (1) · France (1)
John Alam, MD (3) · Hakop Gevorkyan, MD (1) · Philip Scheltens, MD (1)
PMID 33974419, PMID 38706271, PMID 34044875, PMID 36130946, PMID 37657939
2023 (1), R01AG080536 (1)